Completed PHASE2 INTERVENTIONAL 4-arm NCT01320553

Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis

Sponsor: Sun Pharma Advanced Research Company Limited

Interventions SPARC1102 I SPARC1102 II SPARC1102 III Vehicle

Updated 9 times since 2017 Last updated: May 23, 2016 Started: Jun 30, 2011 Primary completion: Aug 31, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Allergic Conjunctivitis, this trial is completed. The trial is conducted by Sun Pharma Advanced Research Company Limited and has accumulated 9 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Pharma Advanced Research Company Limited

Data source: Sun Pharma Advanced Research Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Andover, United States